NCT01597414已完成2 期
Pertuzumab + Trastuzumab (PH) Versus PH Plus Metronomic Chemotherapy (PHM) in the Elderly HER2+ Metastatic Breast Cancer Population Who May Continue on T-DM1 Alone Following Disease Progression While on PH / PHM: an Open-label Multicentre Randomized Phase II Selection Trial of the EORTC Elderly Task Force and Breast Cancer Group
European Organisation for Research and Treatment of Cancer - EORTC30 个研究点 分布在 8 个国家目标入组 80 人开始时间: 2013年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 30
- 主要终点
- Progression free survival rate
研究概览
简要总结
Chemotherapy and HER2 targeted agents can improve survival significantly in metastatic breast cancer. Chemotherapy however is associated with significant side-effects and can impact on Quality of Life and functionality in older patients.
The investigators aim to establish HER2 targeted regimens with minimal toxicity in order to delay or even avoid the use of classical chemotherapy because of competing risks of death in this frail/elderly patient group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically proven HER-2 positive
- •Newly diagnosed or recurrent (after surgery) stage IV disease (TNM/AJCC v.7).
- •Patients must have measurable (RECIST v. 1.1) or evaluable disease
- •Performance status (PS) 0-3 (WHO)
- •Age ≥ 70 years of age, or ≥ 60 years old with required number of dependencies
- •Life expectancy of more than 12 weeks
- •Previous adjuvant chemotherapy/anti HER-2 therapy after surgery is allowed, given that the time interval from end of previous treatment to initiation of treatment for metastatic disease is ≥ 6 months.
- •Up to one line of anti-HER therapy (trastuzumab or lapatinib) is allowed in combination with hormone therapy for hormone sensitive metastatic breast cancer.
- •Adequate organ function
- •Before patient randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
排除标准
- •No brain metastases that are untreated, symptomatic, or require steroids to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastases within 2 months prior to the first study treatment.
- •No prior chemotherapy for metastatic disease is allowed
- •No prior treatment with pertuzumab is allowed
- •No history of exposure to the following cumulative doses of anthracyclines:
- •Doxorubicin or liposomal doxorubicin > 360 mg/m2
- •Epirubicin > 720 mg/m2
- •Mitoxantrone > 120 mg/m2
- •Idarubicin > 90 mg/m2
- •If another anthracycline or more than 1 anthracycline has been used, then the cumulative dose must not exceed the equivalent of 360 mg/m2 of doxorubicin.
- •No history of palliative radiotherapy within 14 days of randomization
- •No history of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin
- •No current uncontrolled hypertension (persistent systolic > 180 mmHg and/or diastolic > 100 mmHg)
- •No LVEF below 50%
- •No history of significant cardiac disease defined as:
- •Symptomatic CHF (NYHA classes II-IV)
- •High-risk uncontrolled arrhythmias
- •History of myocardial infarction within 6 months prior to randomization
- •Clinically significant valvular heart disease
- •No angina pectoris requiring anti-angina treatment
- •No peripheral neuropathy of Grade ≥ 3 per NCI CTCAE version 4.
- •No current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures, known infection with HIV, active hepatitis B and/or hepatitis C virus)
- •No major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment
- •No history of receiving any investigational treatment within 28 days of randomization
- •No history of intolerance (including Grade 3-4 infusion reaction) to trastuzumab
- •No unwillingness or inability to comply with the requirements of the protocol as assessed by the investigator
- •Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
研究组 & 干预措施
Pertuzumab + trastuzumab (PH)
Active Comparator
Pertuzumab + trastuzumab. After progression,patients will be given the option of receiving T-DM1
干预措施: Pertuzumab + trastuzumab (Drug)
PH + metronomic chemotherapy (PHM)
Experimental
Pertuzumab + trastuzumab + metronomic chemotherapy. After progression,patients will be given the option of receiving T-DM1
干预措施: Pertuzumab + trastuzumab + metronomic chemotherapy (Drug)
结局指标
主要结局
Progression free survival rate
时间窗: 6 months after patients in
次要结局
- Overall survival
- Tumor response rate as measured by RECIST v1.1
- Evolution of HRQoL as assessed by EORTC QLQ-C30 and ELD 14(Up to 1 year after treatment start)
- if T-DM1: progression free survival rate(6 months after start of T-DM1 treatment)
- Breast cancer specific survival
- Evolution of geriatric assessment(Up to 1 year after treatment start)
研究者
研究点 (30)
Loading locations...
相似试验
已完成
2 期
Trastuzumab & Pertuzumab Followed by T-DM1 in MBCMetastatic Breast CancerNCT01835236Swiss Group for Clinical Cancer Research208
尚未招募
3 期
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant TherapyBreast CancerNCT04973319Shengjing Hospital450
已完成
2 期
Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trialBreast CancerNCT04307329The Netherlands Cancer Institute12
进行中（未招募）
2 期
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerMetastatic Breast Cancer With a Isolated Brain ProgressionNCT05041842UNICANCER53
进行中（未招募）
2 期
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibBrain MetastasesHuman Epidermal Growth Factor 2 Positive Carcinoma of BreastAdvanced Breast CancerNCT05323955Carey Anders, M.D.48